R&D
Sanofi Abandons Eczema Approval for Amlitelimab, Dealing Another Blow to the OX40 Class
Despite Phase 3 efficacy, Sanofi says its OX40 drug wouldn't meaningfully beat standard care — the latest setback for a once-promising class of immune drugs.